Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567180129> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W1567180129 endingPage "2539" @default.
- W1567180129 startingPage "2533" @default.
- W1567180129 abstract "In a recently reported, randomized trial, it was found that a regimen of irinotecan once every 3 weeks for patients with advanced colorectal carcinoma was associated with a lower incidence of severe diarrhea compared with weekly treatment, and both regimens had similar efficacy.Resource utilization was captured prospectively for all 291 patients who were included in the trial. Utilities were estimated by transformation of the global quality-of-life (QOL) item on the Eastern Organization for Research and Treatment of Cancer QLQ-C30 instrument.Patients in the every-3-week arm incurred an average incremental cost of $1362, because they received higher average weekly doses and because the every-3-week regimen resulted in less toxicity, allowing delivery of 97% of the planned doses compared with delivery of only 75% of the planned doses in the weekly arm. This lower toxicity also resulted in offsetting savings from decreased hospitalization and less requirement for supportive medications. Non-chemotherapy-related treatment administration costs also were lower, because the every-3-week regimen could be delivered with half the number of infusions. Utility declined less in the every-3-week arm, resulting in a saving of 6.3 quality-adjusted days. The base-case cost:utility ratio was $78,627 per quality-adjusted life year for patients on the every-3-week schedule. However, that ratio was very sensitive to the cost of irinotecan.The schedule of irinotecan once every 3 weeks schedule was more costly but achieved lower toxicity, resulting in modestly improved utility. The cost-per-utility ratio was comparable to other commonly accepted contemporary treatments." @default.
- W1567180129 created "2016-06-24" @default.
- W1567180129 creator A5002447665 @default.
- W1567180129 creator A5005809925 @default.
- W1567180129 creator A5013174971 @default.
- W1567180129 creator A5049314303 @default.
- W1567180129 date "2004-10-22" @default.
- W1567180129 modified "2023-10-17" @default.
- W1567180129 title "Two schedules of second-line irinotecan for metastatic colon carcinoma" @default.
- W1567180129 cites W1861968676 @default.
- W1567180129 cites W1868723949 @default.
- W1567180129 cites W1997634268 @default.
- W1567180129 cites W2006824814 @default.
- W1567180129 cites W2051317937 @default.
- W1567180129 cites W2096122707 @default.
- W1567180129 cites W2125942822 @default.
- W1567180129 cites W2314927739 @default.
- W1567180129 doi "https://doi.org/10.1002/cncr.20691" @default.
- W1567180129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15503310" @default.
- W1567180129 hasPublicationYear "2004" @default.
- W1567180129 type Work @default.
- W1567180129 sameAs 1567180129 @default.
- W1567180129 citedByCount "9" @default.
- W1567180129 countsByYear W15671801292013 @default.
- W1567180129 crossrefType "journal-article" @default.
- W1567180129 hasAuthorship W1567180129A5002447665 @default.
- W1567180129 hasAuthorship W1567180129A5005809925 @default.
- W1567180129 hasAuthorship W1567180129A5013174971 @default.
- W1567180129 hasAuthorship W1567180129A5049314303 @default.
- W1567180129 hasConcept C112930515 @default.
- W1567180129 hasConcept C121608353 @default.
- W1567180129 hasConcept C126322002 @default.
- W1567180129 hasConcept C141071460 @default.
- W1567180129 hasConcept C159110408 @default.
- W1567180129 hasConcept C2779951463 @default.
- W1567180129 hasConcept C2780259306 @default.
- W1567180129 hasConcept C2781413609 @default.
- W1567180129 hasConcept C29730261 @default.
- W1567180129 hasConcept C3019080777 @default.
- W1567180129 hasConcept C526805850 @default.
- W1567180129 hasConcept C71924100 @default.
- W1567180129 hasConceptScore W1567180129C112930515 @default.
- W1567180129 hasConceptScore W1567180129C121608353 @default.
- W1567180129 hasConceptScore W1567180129C126322002 @default.
- W1567180129 hasConceptScore W1567180129C141071460 @default.
- W1567180129 hasConceptScore W1567180129C159110408 @default.
- W1567180129 hasConceptScore W1567180129C2779951463 @default.
- W1567180129 hasConceptScore W1567180129C2780259306 @default.
- W1567180129 hasConceptScore W1567180129C2781413609 @default.
- W1567180129 hasConceptScore W1567180129C29730261 @default.
- W1567180129 hasConceptScore W1567180129C3019080777 @default.
- W1567180129 hasConceptScore W1567180129C526805850 @default.
- W1567180129 hasConceptScore W1567180129C71924100 @default.
- W1567180129 hasIssue "11" @default.
- W1567180129 hasLocation W15671801291 @default.
- W1567180129 hasLocation W15671801292 @default.
- W1567180129 hasOpenAccess W1567180129 @default.
- W1567180129 hasPrimaryLocation W15671801291 @default.
- W1567180129 hasRelatedWork W1928747779 @default.
- W1567180129 hasRelatedWork W1976468768 @default.
- W1567180129 hasRelatedWork W2039456992 @default.
- W1567180129 hasRelatedWork W2047348737 @default.
- W1567180129 hasRelatedWork W2103046845 @default.
- W1567180129 hasRelatedWork W2353482984 @default.
- W1567180129 hasRelatedWork W2394693425 @default.
- W1567180129 hasRelatedWork W2412478066 @default.
- W1567180129 hasRelatedWork W2440549043 @default.
- W1567180129 hasRelatedWork W2796096298 @default.
- W1567180129 hasVolume "101" @default.
- W1567180129 isParatext "false" @default.
- W1567180129 isRetracted "false" @default.
- W1567180129 magId "1567180129" @default.
- W1567180129 workType "article" @default.